NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Impact · against what's priced in

NanoViricides' move toward Phase 2 trials for NV-387 in MPox and respiratory infections introduces new catalysts for the stock, specifically potential BARDA funding and expansion into high-value markets. While execution risk remains due to vague filing timelines, the shift from Phase 1 safety to efficacy trials in multiple indications is fundamentally positive.

NNVC+0.60

No priced-in read yet